RuiXin Medical Showcases AngioQFA System at 2026 ME Shenzhen Exhibition, Advancing Precision Coronary Physiology Assessment

From March 31 to April 2, the 2026 ME Shenzhen Medical Device Supply Chain Ecosystem Exhibition was grandly held at the Shenzhen International Convention and Exhibition Center. As an important platform for the entire industry chain of China's medical device industry to promote collaborative innovation, this exhibition brought together many top enterprises and cutting-edge technologies. RaysightMed was invited to participate and showcased its core products on-site.One-stop Coronary Macro + Micro Functional Measurement System AngioQFA, becoming one of the highlights at the exhibition site.

At the thematic forum "AI + Medical Devices: From Precision Diagnosis to Systemic Change" held on the morning of March 31, a representative of RaysightMed delivered a keynote speech.。

In the field of coronary intervention diagnosis and treatment, how to accurately assess the functional significance of vascular lesions has always been a core challenge in clinical practice. Although traditional imaging methods can clearly display the anatomical structure of blood vessels, they have limitations in determining ischemia-related lesions. Meanwhile, guidewire measurement methods are restricted in their widespread clinical application due to factors such as operational complexity and associated risks.

In response to this clinical pain point, RaysightMed has launchedAngioQFA System, based on coronary angiography images, equipped with self-developed intelligent algorithms,Without the need for additional interventions, it is possible to simultaneously complete functional analysis of vascular stenosis and microcirculatory function assessment during a single coronary angiography procedure.`, providing clinicians with more comprehensive and precise decision-making support.`

"The initial intention of developing AngioQFA was to hopeEnable more doctors and patients to benefit from the precise diagnosis and treatment value brought by functional assessment, without increasing surgical risks.". RaysightMed's representative mentioned, "This system not only continues RaysightMed's profound accumulation in the field of hemodynamics but also achieves a breakthrough in the accuracy of clinical applications."

During the exhibition, the AngioQFA system attracted significant attention from industry experts, clinicians, and supply chain partners. Many visitors who experienced the system on-site expressed thatThe operation process is simple, and the results are presented intuitively, showing significant advantages especially in the functional assessment of complex lesions., which is expected to bring a new paradigm for coronary intervention diagnosis and treatment in clinical promotion.

In the future, RaysightMed will continue to focus on the diagnosis and treatment of cardiovascular and cerebrovascular diseases, relying on its independently developed technologies to promote more innovative products into clinical use, helping to achieve the widespread implementation of precision medicine.

RaysightMed Announces Brand Upgrade: Using Intelligent Technology to Protect the Longer Rhythm of Life

Integration of Medicine and Engineering | RaysightMed Attends the Founding Ceremony of the Jinan University Cardiovascular Research Institute Alliance, Jointly Exploring the New Future of AI-empowered Cardiovascular Diagnosis and Treatment

RaysightMed Invited to Attend the Launch and Promotion Meeting of the National Key R&D Program Project "Key Technologies and Application Demonstration of Intelligent Cardiopulmonary Dynamics Simulation and Gas Exchange Simulation"